Study of HPN424 in Patients With Advanced Prostate Cancer

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy

HPN424 will be administered once weekly via IV infusion or subcutaneously with dose escalation until an estimated therapeutic dose level has been reached.

Patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added.

HPN424 will be administered at the recommended phase 2 dose(s) once weekly via IV infusion or subcutaneously.

Assess safety and tolerability at increasing dose levels of HPN424 in successive cohorts of patients with metastatic castrate resistant prostate cancer (mCRPC) to select the recommended Phase 2 dose(s) (RP2D), and dosing regimen for further investigation by measuring incidence of DLTs.

Evaluate preliminary clinical efficacy of HPN424 at recommended phase 2 dose (RP2D) by determining ORR as measured by bone scans, CT/MRI and prostate specific antigen (PSA) levels.

Evaluate the overall safety profile of HPN424 administered by IV infusion or SC injection, as measured by adverse events.

Characterize single dose and multiple dose PK of HPN424 following IV administration by measuring levels of HPN424 in blood serum.

Characterize the impact of HPN424 on activation of circulating lymphocytes and on systemic soluble immune factors by immunophenotyping of lymphocytes in whole blood and measuring cytokines in serum.

Inclusion Criteria: Male patients ≥18 years of age at the time of signing informed consent Histologically or cytologically confirmed adenocarcinoma of the prostate Progressive metastatic castrate-resistant prostate cancer (mCRPC): Serum testosterone levels less than 50 ng/dL (or ≤0.50 ng/mL or 1.73 nmol/L) within 28 days prior to start of study drug Radiographic evidence of metastatic disease Disease progression on the prior systemic regimen, per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria i. A sequence of at least 2 rising PSA values measured at a minimum of 1 week apart with a 2 ng/mL minimum starting value, or ii. Appearance of two or more new lesions on bone scans, or iii. Progressive visceral disease, or iv. Progressive nodal disease; previously normal (<1.0 cm) lymph nodes must have grown by ≥5 mm in the short axis from baseline or nadir and be ≥1.0 cm in the short axis to be considered to have progressed Must have received at least 2 prior systemic therapies approved for mCRPC Ongoing androgen depletion therapy with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration) For patients previously treated with first generation anti-androgens, discontinuation must have occurred ≥4 weeks (for flutamide or nilutamide) or ≥6 weeks (for bicalutamide) prior to start of study drug, with no evidence of an anti-androgen withdrawal response (i.e., no decline in serum PSA) For patients previously treated with a second-generation anti-androgen (e.g., enzalutamide or equivalent) or with abiraterone acetate, discontinuation must have occurred 2 weeks or 5 half-lives prior to start of study drug For patients previously treated with systemic chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent, discontinuation must have occurred ≥2 weeks, or at least 4 half-lives (up to 4 weeks), whichever is longer, prior to start of study drug. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate bone marrow function, including: Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L Platelets ≥100,000/mm3 or ≥100 x 109/L Hemoglobin ≥9 g/dL (no transfusions allowed within 1 week prior to screening) Adequate renal function, including: a. Estimated creatinine clearance ≥50 mL/min as calculated using the method standard for the institution Adequate liver function, including: Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has documented Gilbert syndrome in which case the maximum total serum bilirubin should be 5 mg/dL Aspartate and Alanine transaminase (AST and ALT) ≤2.5 x ULN Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1 except for adverse events (AEs) not constituting a safety risk per the Investigator If of reproductive potential, willing to use 1 effective method of contraception (as defined in this protocol) during the treatment period, if partner is a female of childbearing potential. Willing to complete all scheduled visits and assessments at the institution administering therapy Able to read, understand and provide written informed consent Exclusion Criteria: Previously treated or current brain metastases Untreated spinal cord compression. Participants must be neurologically stable off steroids for at least 4 weeks prior to first dose of study drug Ongoing treatment with anti-tumor necrosis factor (TNF) alpha therapies, systemic corticosteroids (prednisone dose >10 mg per day or equivalent), or other immune suppressive drugs History of or known or suspected autoimmune disease (exception(s): patients with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at Screening are allowed) History of clinically significant cardiovascular disease such as symptomatic congestive heart failure (CHF), uncontrolled hypertension defined as sustained BP >150 mmHg systolic, or >100 mmHg diastolic despite optimal antihypertensive treatment (BP must be controlled at screening), unstable angina pectoris, clinically significant cardiac arrhythmias, history of stroke (including TIA, or other ischemic event) within 6 months before first dose of study drug, myocardial infarction within 6 months before first dose of study drug, history of thromboembolic event within 3 months before first dose of study drug Known active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface antigen (HBsAg) positivity and/or anti-hepatitis C virus (HCV) positivity, respectively, or known history of human immunodeficiency virus (HIV) seropositive status Clinically active liver disease, including liver cirrhosis of Child-Pugh class B or C Second primary malignancy that has not been in remission for greater than 3 years. Exceptions that do not require a 3-year remission: non-melanoma skin cancer, resected melanoma in situ, or non-muscle invasive urothelial carcinoma In the judgment of the Investigator, patient has a clinically significant concurrent illness or psychological, familial, sociological, geographical, or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol Any serious underlying medical or psychiatric condition (e.g., alcohol or drug abuse), dementia or altered mental status or any issue that would impair the ability of the patient to understand informed consent or that in the opinion of the Investigator would contraindicate the patient's participation in the study or confound the results of the study Known hypersensitivity, allergies, or intolerance to immunoglobulins, or to any excipient contained in HPN424 (see Investigator's Brochure) Is a participant or plans to participate in another interventional clinical study, while taking part in this protocol. Participation in an observational study is acceptable